Table 4. Number of patients with serious adverse events.

Serious adverse event	Octreotide-LAR (n = 51)	Placebo (n = 49)
Overall	12 (23.5%)	11 (22.4%)
Pulmonary embolism	1 (2.0%)	0
Myocardial infarction	0	1 (2.0%)
Acute renal failure	2 (3.9%)	2 (4.1%)
Renal cyst rupture or infection	1 (2.0%)	3 (6.1%)
Urinary tract infection	0	1 (2.0%)
Acute pyelonephritis	0	1 (2.0%)
Ureteral obstruction due to lithiasis	0	1 (2.0%)
Sepsis due to Klebsiella pneumoniae	1 (2.0%)	0
Varicella	1 (2.0%)	0
Umbilical hernia	1 (2.0%)	0
Acute pancreatitis	1 (2.0%)	0
Biliary vomiting	1 (2.0%)	0
Abdominal pain	0	1 (2.0%)
Anemia	1 (2.0%)	1 (2.0%)
Fever	1 (2.0%)	0
Pancreatic enzyme elevation	0	1 (2.0%)
Hyperammonemia	1 (2.0%)	0
Acute retinal detachment	1 (2.0%)	0
Genitourinary prolapse	1 (2.0%)	0
Cystocele	1 (2.0%)	0
Menometrorrhagia	1 (2.0%)	0

Data are n (%).

octreotide-LAR, octreotide long-acting release.